Heat-Shock Protein 90-Targeted Nano Anticancer Therapy
Related Experiment Video
Updated: Mar 25, 2026
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Ankit K Rochani1, Aswathy Ravindran Girija1, Ankita Borah1
1Bio Nano Electronics Research Centre, Graduate School of Interdisciplinary Science, Toyo University, Kawagoe, Saitama-350-8585, Japan.
Abstract:
Suboptimal chemotherapy of anticancer drugs may be attributed to a variety of cellular mechanisms, which synergize to dodge the drug responses. Nearly 2 decades of heat-shock protein 90 (Hsp90)-targeted drug discovery has shown that the mono-therapy with Hsp90 inhibitors seems to be relatively ineffective compared with combination treatment due to several cellular dodging mechanisms. In this article, we have tried to analyze and review the Hsp90 and mammalian target of rapamycin (m-TOR)-mediated drug resistance mechanisms. By using this information we have discussed about the rationale behind use of drug combinations that includes both or any one of these inhibitors for cancer therapy. Currently, biodegradable nano vector (NV)-loaded novel drug delivery systems have shown to resolve the problems of poor bioavailability. NVs of drugs such as paclitaxel, doxorubicin, daunorubicin, and others have been successfully introduced for medicinal use. Hence, looking at the success of NVs, in this article we have also discussed the progress made in the delivery of biodegradable NV-loaded Hsp90 and m-TOR-targeted inhibitors in multiple drug combinations. We have also discussed the possible ways by which the market success of biodegradable NVs can positively impact the clinical trials of anti-Hsp90 and m-TOR combination strategy.
Insights
Combination cancer therapy using heat-shock protein 90 (Hsp90) and mammalian target of rapamycin (m-TOR) inhibitors shows promise. Biodegradable nano vectors improve drug delivery, potentially enhancing clinical trial success for these targeted treatments.
Area of Science:
- Oncology
- Pharmacology
- Nanotechnology
Background:
- Suboptimal chemotherapy response is often due to cellular mechanisms that evade drug effects.
- Monotherapy with heat-shock protein 90 (Hsp90) inhibitors has limited efficacy compared to combination treatments.
- Hsp90 and mammalian target of rapamycin (m-TOR) pathways are implicated in cancer drug resistance.
Purpose of the Study:
- To review Hsp90 and m-TOR-mediated drug resistance mechanisms in cancer.
- To discuss the rationale for combining Hsp90 and/or m-TOR inhibitors in cancer therapy.
- To explore the role of biodegradable nano vectors (NVs) in delivering combination therapies.
Main Methods:
- Literature review and analysis of Hsp90 and m-TOR-mediated drug resistance.
- Discussion of combination therapy strategies involving Hsp90 and m-TOR inhibitors.
- Examination of advancements in biodegradable NV drug delivery systems.
Main Results:
- Hsp90 and m-TOR pathways contribute significantly to anticancer drug resistance.
- Combination therapies targeting Hsp90 and m-TOR offer a more effective strategy than monotherapy.
- Biodegradable NVs demonstrate potential for improving bioavailability and delivery of these targeted agents.
Conclusions:
- Combining Hsp90 and m-TOR inhibitors, delivered via biodegradable NVs, presents a promising strategy for cancer treatment.
- Successful development of NV-based drug delivery systems could positively influence clinical trials for these combination therapies.
- Further research into NV-loaded combination therapies is warranted to overcome drug resistance and improve patient outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies